What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both

What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both

Episode 214

We dip into the gene therapy pool one more time, talking with Jay Duker, MD about Luxturna’s impact on ophthalmology. We also discuss how the acquisitions of Spark and Nightstar are benefiting earlier-stage gene therapy start-ups, including his own Hemera Biosciences.

Do You Have

A STORY TO TELL?

If you’d like to be considered as a guest on a future episode of the OIS podcast, please complete the application today.

Meet Our Host

TOM SALEMI

Tom-Salemi

Joining the company in 2014, to create and manage a new line of podcasts, publications and other editorial products.

Subscribe

ON iTUNES

Don't miss an episode. Join the conversation by visiting our podcast channel on iTunes today and subscribe. It's fast and free!

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.